×

Biotech and Pharmaceuticals Pharmaceuticals

  • Oil's 'false tell' could set off domino effect

    Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.

  • Cramer: How oil's 'false tell' could set off a market-changing domino effect

    Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.

  • A floorhand works on an oil rig in the Bakken shale formation outside Watford City, North Dakota.

    Jim Cramer says oil prices bottoming could have an effect on investors' stock picks.

  • Mixed bag for biotech earnings

    CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.

  • Vertex Pharma earnings beat $0.41 vs. $0.39 est.

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' quarterly earnings.

  • Take Macy's, Wal-Mart and Nike, all retailers. Macy's, a department store operator, makes all of its revenue in the U.S., according to FactSet, while Wal-Mart gets about a quarter of its revenue outside the U.S. and Nike makes almost 60 percent of its sales in countries other than the U.S. That's one important reason Macy's pays higher taxes.

  • Elon Musk, CEO of Tesla.

    Tesla executive Klaus Grohmann was ousted last month after a clash with Chief Executive Elon Musk over the strategy of Grohmann's firm.

  • FRANKFURT, April 27- Tesla executive Klaus Grohmann was ousted last month after a clash with Chief Executive Elon Musk over the strategy of Grohmann's firm, which Tesla had acquired in November, a source familiar with the matter told Reuters. At the time of the purchase, it described Klaus Grohmann and the company he founded as a "world leader in highly automated...

  • The suburban Chicago drugmaker's cancer drug Imbruvica raked in first-quarter sales of $551 million, while its hepatitis C treatment, Viekira Pak, brought in $263 million. Net profit rose to $1.71 billion, or $1.06 per share, in the first quarter ended March 31, from $1.35 billion, or 83 cents per share, a year earlier. Excluding items, the company earned $1.28,...

  • The treatment generated sales of $4.12 billion, ahead of the Street estimate of $4.09 billion, according to Barclays. The U.S. drugmaker's net profit rose to $1.71 billion, or $1.06 per share, in the first quarter ended March 31, from $1.35 billion, or 83 cents per share, a year earlier. Excluding items, the company earned $1.28, beating the average analyst estimate by 2...

  • April 27- AbbVie Inc reported a 26.4 percent jump in quarterly profit on Thursday, helped by higher demand for its top-selling treatment, Humira. The U.S. drugmaker's net profit rose to $1.71 billion, or $1.06 per share, in the first quarter ended March 31, from $1.35 billion, or 83 cents per share, a year earlier. Net revenue rose to $6.54 billion from $5.96 billion.

  • MUMBAI, April 27- India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a...

  • LONDON— Anglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year. Net income fell to $537 million, from $646 million. CEO Pascal Soriot said Thursday that the impact of recent patent expirations should ease this year as he highlighted optimism about...

  • SEOUL, April 27- South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won for offering doctors kickbacks to recommend the company's drugs, and also suspended insurance coverage for some of its drugs. The Ministry of Health and Welfare said in a statement that it has preliminarily decided to suspend insurance coverage of nine...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • April 26- Key healthcare stakeholders, led by the World Economic Forum, plan pilot programs this year to show the value of a new model for healthcare that would track and pay for treatment based on how well it works rather than the volume of care. The first pilot, being set up in Atlanta, Georgia, will focus on treating heart failure. Signatories include Novartis AG,...

  • Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals, departs following a hearing at a U.S. federal court in New York City on June 6, 2016.

    Shkreli is accused of defrauding his former drug company out of millions to pay back hedge-fund investors he allegedly ripped off.

  • April 26- Merck& Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year. The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Vytorin, while Teva...

  • April 26- The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck& Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales. Zetia generated 2016 sales of $2.6 billion. Merck faces generic competition this year not only to Vytorin and...

  • WASHINGTON, April 26- U.S. Supreme Court justices on Wednesday struggled over whether to speed up the time it takes to bring to the market copycat versions of biologic drugs, expensive medicines that can generate billions of dollars in sales for drug makers. The nine justices heard arguments in an appeal by Novartis AG of a lower court decision that prevented the...